Loading organizations...
§ Private Profile · Kurume, Fukuoka, Japan
Develops small-molecule therapeutics targeting ferroptosis for neonatal retinal diseases in ophthalmology, preventing ROP.
FELIQS is a Fukuoka, Japan and New York-based biotechnology company that develops small molecule therapeutics targeting ferroptosis and oxidized lipids to treat unmet needs in pediatric ophthalmology. The organization's lead candidate, FLQ-101, is an oral and intravenous therapy advancing to Phase 1b/2 clinical trials to prevent retinopathy of prematurity in preterm infants. Operating with a team of three employees, the enterprise recently secured $9 million in Series A funding to finance its upcoming clinical studies. This financing round included investments from Beyond Next Ventures, Mitsubishi UFJ Capital, and Keio Innovation Initiative. The therapeutic candidate previously received Orphan Drug and Fast Track designations from the United States Food and Drug Administration, while Gregory Kunst and Joe Zenkus joined the board of directors. FELIQS was founded in 2019 by Kenichiro Kuninobu as a spinout from Kyushu University.
FELIQS has raised $9.0M across 1 funding round.
FELIQS has raised $9.0M in total across 1 funding round.
FELIQS has raised $9.0M across 1 funding round. Most recently, it raised $9.0M Series A in July 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2025 | $9M Series A | Beyond Next Ventures | FFG Venture Business Partners, Japan Science And Technology Agency, Keio Innovation Initiative, Mitsubishi UFJ Capital | Announced |
FELIQS has raised $9.0M in total across 1 funding round.
FELIQS's investors include Beyond Next Ventures, FFG Venture Business Partners, Japan Science and Technology Agency, Keio Innovation Initiative, Mitsubishi UFJ Capital.